Trane Technologies stock jumps 8% after earnings beat as record backlog, 2026 outlook take spotlight
30 January 2026
1 min read

Trane Technologies stock jumps 8% after earnings beat as record backlog, 2026 outlook take spotlight

New York, Jan 29, 2026, 20:54 EST — Market closed

  • TT jumped roughly 8% following its fourth-quarter results and the release of 2026 guidance
  • Organic bookings climbed 22% during the quarter, pushing the year-end backlog to a record $7.8 billion
  • Earnings call highlighted strong demand for data-center cooling but flagged weakness in residential and transport sectors

Trane Technologies plc (TT) shares jumped $31.61, roughly 8%, to $426.07 following Thursday’s close. The heating and cooling equipment maker unveiled its quarterly earnings and shared its outlook through 2026.

This matters going into Friday’s session since Trane’s order trends are seen as a gauge for commercial building demand and major project spending, not just a standalone company report. Earlier Thursday, a regulatory filing revealed the company’s fourth-quarter and full-year results.

Trane reported a 22% rise in organic bookings for the quarter, excluding currency fluctuations and acquisitions, with its backlog reaching a record $7.8 billion at the end of the year. This backlog represents orders yet to be shipped and offers a glimpse into revenue lined up for upcoming quarters.

On the earnings call, CEO Dave Regnery dismissed rumors that changes in data-center cooling could make chillers obsolete. “We see chillers in the data center vertical well into the future,” he insisted. The Motley Fool

Adjusted earnings came in at $2.86 per share on $5.15 billion in revenue, beating analysts’ expectations of $2.82 and $5.09 billion, respectively, according to Investing.com. The site noted Trane’s 2026 EPS outlook of $14.65 to $14.85 aligns closely with consensus estimates.

The company’s latest quarterly report highlighted a surge in commercial HVAC demand across the Americas, with applied equipment bookings soaring over 120%, the release showed. Trane also posted a book-to-bill ratio of 112%, signaling that orders outpaced sales bookings.

Trane posted $21.32 billion in revenue for full-year 2025, with adjusted EPS hitting $13.06. GAAP operating margin improved by 100 basis points — remember, one basis point equals one-hundredth of a percentage point. Looking ahead to 2026, the company expects reported revenue growth between 8.5% and 9.5%, while organic revenue should grow roughly 6% to 7%.

Trane reported full-year free cash flow of about $2.9 billion, representing 98% of adjusted net earnings. The company deployed or committed roughly $3.2 billion, including around $1.5 billion for share buybacks and about $840 million in dividends.

But the picture isn’t clear-cut across the board. Executives noted on the call that residential margins took a hit due to steps aimed at normalizing inventory. They called the first quarter in residential the trough, down roughly 20% year over year. Transport demand remains weak as well. The company also confirmed its Stellar Energy acquisition should close in the first quarter, adding integration challenges amid already uneven demand.

Traders will be eyeing Friday’s regular session (Jan. 30) to see if TT maintains its post-earnings gains, while also looking out for new broker notes that might shift the outlook on HVAC rivals like Carrier Global and Johnson Controls.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • XBI Tops PBE in Biotech ETF Returns, Strategies Diverge on Risk and Fees
    July 24, 2026, 9:07 AM EDT. The SPDR S&P Biotech ETF (XBI) delivered a 73% return in one year, significantly ahead of the Invesco Biotechnology & Genome ETF (PBE)'s 35% gain, boosted by XBI's equal weighting of more than 100 biotech stocks and its lower 0.35% expense ratio versus PBE's 0.58%. During the 2021-2022 sector slump, however, PBE's focus on quality and large-cap stocks resulted in five-year returns that matched XBI's 20% but with reduced volatility, underscoring the differences in their investment approaches.
Intel stock dips before the bell after report ties Nvidia, Apple to future chip work
Previous Story

Intel stock dips before the bell after report ties Nvidia, Apple to future chip work

Hang Seng slips at open as Alibaba, Tencent slide — yet Hong Kong stocks eye best month in four
Next Story

Hang Seng slips at open as Alibaba, Tencent slide — yet Hong Kong stocks eye best month in four